SG 2000

Drug Profile

SG 2000

Alternative Names: BN-2629; NCI 694501; NSC 694501; Project P011; SJG-136; SP 2001; UP-2001

Latest Information Update: 03 Dec 2015

Price : $50

At a glance

  • Originator Spirogen
  • Developer National Cancer Institute (USA); Spirogen
  • Class Benzodiazepines; Cytostatic antibiotics; Pyrroles
  • Mechanism of Action DNA cross linking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia; Chronic lymphocytic leukaemia
  • Discontinued Fallopian tube cancer; Ovarian cancer; Peritoneal cancer

Most Recent Events

  • 03 Dec 2015 Spirogen terminates a phase I/II trial for Chronic lymphocytic leukaemia and Acute myeloid leukaemia (Second-line therapy or greater, Late stage disease) in USA (NCT02034227)
  • 15 Oct 2013 Spirogen has been acquired by MedImmune
  • 31 Jul 2013 The National Cancer Institute terminates a phase II trial in Ovarian cancer, Peritoneal cancer & Fallopian tube cancer in USA (NCT01200797)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top